User:Kyle091089/Rotigaptide

{subst:AFC submission/submit}}

This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft.

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL
Easy tools: Citation bot (help) | Advanced: Fix bare URLs
This page was last edited by [[User:|]] ([[User talk:|talk]] | contribs) 0 seconds ago. (Update timer)

Finished writing a draft article? Are you ready to request an experienced editor review it for possible inclusion in Wikipedia? Save your work by pressing the "Publish page" button below, and a button will appear here allowing you to submit your draft for review.

Rotigaptide (ZP-123) is a stable gap junction conduction-enhancing antiarrhythmic peptide analogue that has been shown to increase gap junction intercellular conductance in cardiac myocytes. ^[1] Gap junctions are protein channels that are responsible for conducting electrical impulses between cells in the heart to maintain normal rhythm. It is currently under clinical investigation for the treatment of cardiac arrhythmias – specifically, atrial fibrillation. Gap junction modulation is a promising and novel mechanism of action for the treatment of cardiovascular disorders. ^[1]

^ ^a ^b Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan J, Nattel S (2007). Model- Dependent Effects of the Gap Junction Conduction–Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs. Circulation. 115: 310- 318.

[intro-1] Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan J, Nattel S (2007). Model- Dependent Effects of the Gap Junction Conduction–Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs. Circulation. 115: 310- 318.

[1]